ArticleClinical pharmacology and therapeutics2025

Model-Informed Drug Development-Based Bridging from Subcutaneous to Intravenous Secukinumab Dosing: Approval in Psoriatic Arthritis and Axial Spondyloarthritis.

Thomas Dumortier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.